An Ernst & Young report shows a mixed bag across the whole sector.

A new funding round for Checkmate Pharma will fund additional trials of immuno-oncology drug CMP-001.

Ocugen has raised $7.5 million in a series B round as it fixes its sights on advancing a trio of eye disease treatments into clinical trials.

Novartis and Verily have helped Medicxi raise $300 million to invest in late-stage drug developers.

LifeArc has set up a seed fund to invest in early preclinical projects that are overlooked because of the high risk of failure at that stage of R&D.

Life sciences VC Flagship Pioneering has been attracting some big names to its top management and shows no signs of letting up.

The British biopharma industry is facing further uncertainty after last week’s general election left the country without a clear ruling party.

Roivant has launched yet another new biotech, this time focused on urologic disorders

Texas startup Lung Therapeutics has got off a $14.3 million series B round as it eyes the cash boost for its trials in fibrosis, lung injury and disease.

Bioblast Pharma has asked JSB-Partners to help it seek out a partner or a merger.

Venture Capital